Keytruda exceeds expectations to keep Merck & Co sales steady

2 February 2017

Merck & Co’s (NYSE:MRK) 2016 financial results offer further evidence of why the company is the envy of the industry due to its ownership of the immuno-oncology drug Keytruda (pembrolizumab).

The US pharma giant reported a narrow rise in its sales figures for the year, and this was thanks largely to a 148% rise in revenue from the anti-PD-1 therapy, which is being approved in new cancer indications across the world with every passing month.

"The momentum behind our pipeline and key product launches, including the continued growth and expansion of Keytruda into new indications and markets, further reinforces our company's strategic direction"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK